Bristol-Myers Squibb Co (BMY) : Legal General Group Plc reduced its stake in Bristol-Myers Squibb Co by 0.26% during the most recent quarter end. The investment management company now holds a total of 7,911,168 shares of Bristol-Myers Squibb Co which is valued at $391,998,374 after selling 20,912 shares in Bristol-Myers Squibb Co , the firm said in a disclosure report filed with the SEC on Oct 12, 2016.Bristol-Myers Squibb Co makes up approximately 0.40% of Legal General Group Plc’s portfolio.
Other Hedge Funds, Including , Hexavest boosted its stake in BMY in the latest quarter, The investment management firm added 671,584 additional shares and now holds a total of 682,212 shares of Bristol-Myers Squibb Co which is valued at $33,803,605. Bristol-Myers Squibb Co makes up approx 0.62% of Hexavest’s portfolio.Cutler Group Lp boosted its stake in BMY in the latest quarter, The investment management firm added 10,425 additional shares and now holds a total of 14,825 shares of Bristol-Myers Squibb Co which is valued at $738,433. Bristol-Myers Squibb Co makes up approx 0.05% of Cutler Group Lp’s portfolio.Perkins Coie Trust Co boosted its stake in BMY in the latest quarter, The investment management firm added 68 additional shares and now holds a total of 2,239 shares of Bristol-Myers Squibb Co which is valued at $111,525. Bristol-Myers Squibb Co makes up approx 0.07% of Perkins Coie Trust Co’s portfolio.First Mercantile Trust Co reduced its stake in BMY by selling 1,074 shares or 12.12% in the most recent quarter. The Hedge Fund company now holds 7,791 shares of BMY which is valued at $431,855. Bristol-Myers Squibb Co makes up approx 0.06% of First Mercantile Trust Co’s portfolio.Burns J W Co Incny reduced its stake in BMY by selling 10,359 shares or 6.28% in the most recent quarter. The Hedge Fund company now holds 154,599 shares of BMY which is valued at $8,470,479. Bristol-Myers Squibb Co makes up approx 2.62% of Burns J W Co Incny’s portfolio.
Bristol-Myers Squibb Co closed down -0.26 points or -0.52% at $49.55 with 2,45,32,533 shares getting traded on Tuesday. Post opening the session at $49.67, the shares hit an intraday low of $49.5 and an intraday high of $50.23 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Bristol-Myers Squibb Co reported $0.69 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.66. The company had revenue of $4881.00 million for the quarter, compared to analysts expectations of $4657.63 million. The company’s revenue was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.53 EPS.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Shares were Reiterated by Barclays on Sep 9, 2016 to “Equal Weight” and Lowered the Price Target to $ 65 from a previous price target of $75 .Bristol-Myers Squibb Co was Downgraded by Berenberg to ” Hold” on Aug 11, 2016. Credit Suisse Downgraded Bristol-Myers Squibb Co on Aug 8, 2016 to ” Neutral”, Price Target of the shares are set at $63.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.